Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Advances in Anatomic Pathology
|
September 26, 2006
Diagnostic Immunohistochemistry: what can go wrong?
Hadi Yaziji, Todd Barry
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2018
A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Troy Bremer, Pat W Whitworth, Rakesh Patel, et al.
Journal of Ovarian Research
|
January 8, 2013
Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer
Shelly Gunn, Xavier Reveles, Korrie Weldon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2020
Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Sheila Weinmann, Michael C Leo, Melanie Francisco, et al.
Cancers
|
December 10, 2021
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)
Fredrik Wärnberg, Per Karlsson, Erik Holmberg, et al.
American Journal of Clinical Pathology
|
June 19, 2012
Immunohistochemistry cocktails are here to stay: Center for Medicare and Medicaid Services should revise its new reimbursement policy
Hadi Yaziji, Richard Eisen, Mark Wick, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
June 19, 2012
Immunohistochemistry cocktails are here to stay: Center of Medicare and Medicaid Services should revise its new reimbursement policy
Hadi Yaziji, Richard Eisen, Mark Wick, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Advances in Anatomic Pathology
|
September 26, 2006
Diagnostic Immunohistochemistry: what can go wrong?
Hadi Yaziji, Todd Barry
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2018
A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Troy Bremer, Pat W Whitworth, Rakesh Patel, et al.
Journal of Ovarian Research
|
January 8, 2013
Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer
Shelly Gunn, Xavier Reveles, Korrie Weldon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2020
Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Sheila Weinmann, Michael C Leo, Melanie Francisco, et al.
Cancers
|
December 10, 2021
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)
Fredrik Wärnberg, Per Karlsson, Erik Holmberg, et al.
American Journal of Clinical Pathology
|
June 19, 2012
Immunohistochemistry cocktails are here to stay: Center for Medicare and Medicaid Services should revise its new reimbursement policy
Hadi Yaziji, Richard Eisen, Mark Wick, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
June 19, 2012
Immunohistochemistry cocktails are here to stay: Center of Medicare and Medicaid Services should revise its new reimbursement policy
Hadi Yaziji, Richard Eisen, Mark Wick, et al.
Page
of 1